Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
137.00    -8.00 (-5.52%)
Bid:
137.00
Ask:
140.00
Spread: 3.00 (2.19%)
Market Cap: £107.51m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Update

14 Jul 2022 07:00

RNS Number : 4114S
Xaar PLC
14 July 2022
 

 

Xaar plc

 

Trading Update

 

Xaar plc ("Xaar", the "Group" or the "Company"), the leading inkjet printing technology group, today announces a trading update for the six months ended 30 June 2022.

 

 

TRADING

 

Continued strong trading and momentum

 

· Revenue for the period is expected to be approximately £37 million, representing an increase of 41% relative to H1 2021 (14% organic excluding FFEI and Megnajet) and 12% relative to H2 2021 (11% organic excluding Megnajet)

 

· Strong revenue growth with improved gross margins and successful cost management actions mean the Board expects the Group to be on track to report an adjusted profit for the current year in line with its expectations

 

Further operational and strategic progress across the Group

 

· Printhead division performed well with strong growth in Europe and US offsetting a Covid-related slowdown in China. We remain on track for the aqueous printhead launch in Q4 2022

 

· The new printbar product developed by FFEI, Xaar Versatex, was successfully launched, whilst the acquisition of Megnajet further strengthens the Group's vertical integration capability

 

· Product Print Systems business ("EPS") delivered a strong, improved performance with revenue and margin growth

 

Successfully mitigating cost inflation

 

· Further investment in inventory has allowed the Group to successfully mitigate cost inflation and increases supply chain resilience

 

· Sales price increases have further assisted in off-setting the effects of cost inflation

 

· Additional management initiatives are helping in reducing costs and increasing operational efficiency while cutting energy use supporting Xaar's 'net zero' commitments

 

 

BALANCE SHEET AND LIQUIDITY

 

The Group remains well capitalised with a strong balance sheet and cash position. Investment has been made in acquiring Megnajet and key capital projects together with increasing working capital to protect the Group's supply chain and ability to deliver products on time. Net cash at 30 June 2022, was £12.6 million, in line with management expectations.

 

 

John Mills, Chief Executive Officer, commented:

 

"We are really pleased to have achieved a strong performance in the first half of the year in line with our expectations. We are on target, seeing positive momentum continuing to improve performance across the Group.

 

We continue to make strategic and operational progress and remain on track to delivering long-term profitable growth.

 

Despite a continued uncertain macro-economic outlook, we remain confident and excited by the future and look forward to the launch of our aqueous printhead later in the year." 

 

 

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Tulchan Communications

Giles Kernick

Olivia Lucas

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKNBKCBKDCOD
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.